HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

'Biopharma ecosystem is back to full health,' fueled by M&A: PwC

With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the "biopharma ecosystem is back to full health."

By FiercePharma · Jun 17, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling
The WeekFierceBiotech ↗
With a panel of outside experts set to weigh in Thursday-and with a refusal-to-file fiasco with the FDA just b…
Jun 17, 2026
Medicare Set to Cover Weight Loss Drugs Under Temporary Program
The WeekBriefing
Starting next month, Medicare will offer weight loss drug coverage through a temporary program that observers …
Jun 17, 2026
A new Westlake-backed biotech takes aim at migraines
The WeekBioPharma Dive ↗
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing "anti…
Jun 17, 2026